The direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, and edoxaban,
are becoming the most commonly prescribed drugs for preventing ischemic stroke in …

A large body of evidence suggests that not only direct anticoagulant effects but also major
bleeding events and stroke prevention depend on plasma concentrations of direct oral …

Compared with warfarin, the direct-acting oral anticoagulants (DOAC) have fewer
pharmacokinetic drug interactions. However, significant drug interactions do exist with …

Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …

Current guidelines from the European Society of Cardiology and American Heart
Association widely recommend direct oral anticoagulants (DOACs) instead of vitamin K …

Concomitant use of direct oral anticoagulants (DOACs) and medications with
inhibition/induction effect on P‐gp/CYP3A might increase risk of bleeding/treatment failure …

Direct oral anticoagulants (DOACs) have rapidly become the drug class of choice for
anticoagulation therapy in secondary care. It is known that gastrointestinal hemorrhage are …

Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K
antagonists (VKAs) to prevent stroke in patients with nonvalvular atrial fibrillation and to …

Due to their mechanism of action, the new oral anticoagulants are named direct oral
anticoagulants (DOACs). Dabigatran is a selective, competitive, direct inhibitor of thrombin …

The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned
by clinicians worldwide due to warfarin several limitations (a limited therapeutic window and …